Skip to search formSkip to main contentSkip to account menu

GSK2256098

Known as: FAK Inhibitor GSK2256098, Focal Adhesion Kinase Inhibitor GSK2256098 
A focal adhesion kinase-1 (FAK) inhibitor with potential antiangiogenic and antineoplastic activities. FAK inhibitor GSK2256098 inhibits FAK, which… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

AminopyridinesHydroxamic Acids
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials
ABSTRACT Introduction: Focal adhesion kinase (FAK) is a promising target for the treatment of solid tumors because its expression… 
Highly Cited
2019
Highly Cited
2019
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours
Combined focal adhesion kinase (FAK) and MEK inhibition may provide greater anticancer effect than FAK monotherapy. This dose… 
Highly Cited
2019
Highly Cited
2019
WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer.
2019
2019
BI 853520, a FAK-Simile of Prior FAK Inhibitors?
2018
2018
A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma (PDAC) (MOBILITY-002 Trial, NCT02428270).
409Background: MEK (mitogen-activated protein kinase kinase) is activated through mutated KRAS in > 90% of PDAC. Focal adhesion… 
2015
2015
A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors.
2593 Background: The focal adhesion kinase (FAK) and MAPK pathways share common upstream activators and contribute to cell… 
2015
2015
PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer
PTEN is known to be frequently mutated in uterine cancer and also dephosphorylates FAK. Here, we examined the impact of PTEN… 
2015
2015
ATNT-06EVALUATION OF THE SAFETY OF GSK2256098 AND PHARMACOKINETICS OF 11C-GSK2256098 IN PATIENTS WITH RECURRENT GLIOBLASTOMA BY POSITRON EMISSION TOMOGRAPHY (PET) IMAGING.
BACKGROUND: Focal adhesion kinase (FAK) is overexpressed in glioblastoma (GBM) and is associated with poor prognosis. The FAK… 
2012
2012
Phase I clinical and pharmacologic study of the focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with advanced solid tumors.
3000 Background: FAK has an important role in cancer invasion and metastasis. FAK and phospho-FAK (pFAK) are increased in… 
Review
2011
Review
2011
Clinical importance and potential use of small molecule inhibitors of focal adhesion kinase.
Since its first description Focal Adhesion Kinase (FAK), a cytoplasmatic tyrosine kinase, has been implicated in the formation… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)